(PRWEB) February 19, 2013
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is continuing to keep the public informed about recent news concerning the Type 2 diabetes Actos (pioglitazone) and bladder cancer. According to a Bloomberg report published on February 15th, court filings suggest that Takeda was concerned about the impact a bladder cancer warning would have on Actos sales. Actos is the subject of thousands of lawsuits alleging bladder cancer as well as other injuries.
“This information suggests that Actos never possessed the safety profile that Takeda publicly claimed the product had. It raises serious questions about whether the claimed benefits of Actos have ever outweighed the additional risks it posed to diabetic patients,” said Matthew J. McCauley, Senior Litigation Counsel at Parker Waichman LLP. The national personal injury firm offers free legal advice to Actos users who feel they were injured by use of the drug. Parker Waichman has continued to file lawsuits on behalf of Actos patients who allege bladder cancer. One of the firm’s more recent cases was filed on February 5th in the U.S. District Court for the Western District of Louisiana, Lafayette Division (Case No. 6:13-cv-0267); the lawsuit alleges that Actos caused bladder cancer in a Pennsylvania man after he started taking the drug in 2009. The lawsuit is only one example of many similar cases filed by Parker Waichman LLP.
According to Bloomberg, Takeda is facing thousands of lawsuits alleging Actos caused bladder cancer and other injuries. Takeda Pharmaceuticals has insisted that the diabetes drug does not cause bladder cancer. However, court filings show that the company was worried about the issue to some degree; Takeda had surveyed a dozen doctors in 2003 to find out whether they would prescribe a medication that carried a bladder cancer warning. Attorneys for Jack Cooper, whose Actos lawsuit is set to go to trial today in Los Angeles state court, say that the survey showed that a bladder cancer warning would have a detrimental effect on sales of the drug. The case is Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles).
A number of Actos lawsuits are pending in the U.S. District Court for the Western District of Louisiana as part of the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Judge Rebecca Doherty is presiding over the litigation. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiff’s Steering Committee.
In June 2011, use of Actos was suspended in France and Germany due to its association with bladder cancer. At around the same time, the U.S. Food and Drug Administration (FDA) updated the label on Actos to warn that it may increase the risk of bladder cancer after one year of use. Since then, studies have continued to support a link between Actos and bladder cancer. Last May, the British Medical Journal (BMJ) published a study showing that patients who took Actos for two years were twice as likely to get bladder cancer. Another study, published last summer in the Canadian Medical Association Journal, found that use of Actos was linked to a 22 percent increased risk of developing bladder cancer.
Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney